× Medicines Discovery Catapult

Today (6th July 2018) our CEO, Chris Molloy, was awarded Membership of the Institute of Cancer Research (ICR) at a ceremony in London. Membership is awarded in recognition of his input to the ICR Confidence in Concept panel and Finance and Audit committee.

The ICR is one of the world’s most influential cancer research organisations. Focussed on unravelling the complexities of cancer and improving personalised medicine by discovering new treatments that take into account the genetic triggers that vary from one person to the next.

CEO, Chris Molloy, says:
“The ICR is a world class centre of translational research and drug discovery. It’s researchers, clinicians and drug discoverers have a global impact on cancer and the UK’s reputation in the field. I am honoured to be associated with ICR and its ethic of team science.”

Chief Executive and President of ICR, Professor Paul Workman, says:“Chris has a long professional and personal association with ICR and its people. His Membership of ICR recognises this, and his ongoing support of our work to discover new cancer therapeutics and in our corporate financial governance.”

Share